BioNxt Solutions Announces Debenture Unit Financing

Rhea-AI Summary

BioNxt Solutions has announced a non-brokered private placement of debenture units to raise up to $2.5 million. Each debenture unit consists of $0.50 in principal amount, bearing an 8% annual interest rate for two years, and is convertible into common shares. The units also include one Common Share purchase warrant exercisable at $0.60 for two years.

The company may pay interest through common shares at $0.50 per share. Additionally, BioNxt plans to issue up to 400,000 compensation warrants at $0.50 per warrant to eligible finders, along with up to 8% finder's fee in cash. All securities will have a four-month and one-day hold period from issuance. The offering's completion is subject to regulatory approvals.

Positive

• Raising up to $2.5 million in new capital
• 8% interest rate offering attractive terms for investors
• Flexible payment structure allowing interest payment through share issuance

Negative

• Potential dilution of existing shareholders through conversion of debentures and warrants
• Additional dilution from finder's warrants and fees
• High 8% interest rate indicates expensive financing terms

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:4XT), announces a non-brokered private placement of debenture units (the "Debenture Units") with each unit consisting of $0.50 in principal amount of debenture bearing interest at a rate of 8.0% per annum for a period of two years following the closing date (the "Debenture"), convertible into a common share in the capital of the Company (a "Common Shares"), and one Common Share purchase warrant exercisable at $0.60 for a period of two years (a "Warrant"), for gross aggregate proceeds of up to $2,500,000 (the "Offering"). At the election of the Company, the interest payable on the principal amount of the Debentures may be paid through the issuance of Common Shares at a price of $0.50 per Common Share. The principal amount of the Debentures is convertible at the option of the holder at any time prior to the maturity date.

The Company anticipates issuing up to 400,000 compensation warrants (the "Finders Warrants") exercisable into one common share in the capital of the Company each at $0.50 per Finders Warrant, to eligible finders who introduce subscribers for the Offering to the Company, in addition to paying a finder's fee in cash of up to 8% of the subscriptions so introduced.

All securities issued in connection with the Offering, including the Finders Warrants, will be subject to a hold period of four months and one day from the date of issuance. Completion of the Offering is subject to a number of conditions, including but not limited to, receipt of any regulatory approvals as necessary.

This news release does not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Debentures, Warrants, and the underlying Common Shares which may be issued on exercise of each, have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

BioNxt Solutions Inc.

Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 604-250-6162

Cautionary Statement Regarding "Forward-Looking" Information

Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.

SOURCE: BioNxt Solutions Inc.

View the original press release on ACCESS Newswire

FAQ

What is the size of BioNxt Solutions' (BNXTF) February 2025 debenture offering?

BioNxt Solutions is raising up to $2.5 million through a non-brokered private placement of debenture units.

What are the key terms of BNXTF's February 2025 debenture units?

Each debenture unit includes $0.50 principal amount bearing 8% annual interest for two years, convertible to common shares, plus a warrant exercisable at $0.60 for two years.

How many finder's warrants will BNXTF issue for the February 2025 offering?

BioNxt Solutions plans to issue up to 400,000 compensation warrants at $0.50 per warrant to eligible finders.

What is the hold period for BNXTF's February 2025 debenture securities?

All securities issued in the offering will have a hold period of four months and one day from the date of issuance.